Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arrowhead Pharma (NQ: ARWR )

22.30 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arrowhead Pharma

< Previous 1 2 3 4 5 6 Next >
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Making Surprising Moves in Thursday Session
Via Investor Brand Network
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Highlighted for Surprising Price Action
Via Investor Brand Network
Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Want Diversified Upside in Biotechnology? Check out LABU
Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.